Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) have been assigned an average recommendation of “Moderate Buy” from the eleven research firms that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, nine have given a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $38.7778.

Several equities research analysts recently commented on TEVA shares. Jefferies Financial Group boosted their price objective on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, January 6th. The Goldman Sachs Group boosted their price objective on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday, January 21st. JPMorgan Chase & Co. boosted their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 16th. Finally, Piper Sandler reissued an “overweight” rating and set a $41.00 price objective (up from $40.00) on shares of Teva Pharmaceutical Industries in a research note on Wednesday, March 4th.

Insider Transactions at Teva Pharmaceutical Industries

In other news, CEO Richard D. Francis sold 442,935 shares of the company’s stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $32.36, for a total value of $14,333,376.60. Following the transaction, the chief executive officer owned 642,099 shares in the company, valued at approximately $20,778,323.64. This represents a 40.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Mark Sabag sold 62,102 shares of the company’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $30.14, for a total transaction of $1,871,754.28. Following the completion of the transaction, the insider owned 224,940 shares in the company, valued at approximately $6,779,691.60. This represents a 21.64% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 920,901 shares of company stock valued at $30,056,789. 0.54% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Phoenix Financial Ltd. lifted its stake in shares of Teva Pharmaceutical Industries by 9.4% in the third quarter. Phoenix Financial Ltd. now owns 41,295,244 shares of the company’s stock worth $834,164,000 after buying an additional 3,533,800 shares in the last quarter. National Pension Service raised its holdings in shares of Teva Pharmaceutical Industries by 24.2% during the third quarter. National Pension Service now owns 2,073,293 shares of the company’s stock valued at $41,881,000 after purchasing an additional 404,526 shares during the last quarter. Public Sector Pension Investment Board raised its holdings in shares of Teva Pharmaceutical Industries by 11.5% during the third quarter. Public Sector Pension Investment Board now owns 670,467 shares of the company’s stock valued at $13,543,000 after purchasing an additional 69,000 shares during the last quarter. Oak Harvest Investment Services purchased a new position in shares of Teva Pharmaceutical Industries during the third quarter valued at approximately $1,010,000. Finally, Harel Insurance Investments & Financial Services Ltd. raised its holdings in shares of Teva Pharmaceutical Industries by 12.9% during the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 37,696,690 shares of the company’s stock valued at $761,455,000 after purchasing an additional 4,306,363 shares during the last quarter. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Trading Up 2.0%

NYSE:TEVA opened at $31.76 on Wednesday. Teva Pharmaceutical Industries has a one year low of $13.04 and a one year high of $37.35. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.04 and a quick ratio of 0.80. The company’s 50-day simple moving average is $31.70 and its 200 day simple moving average is $28.44. The firm has a market capitalization of $36.52 billion, a P/E ratio of 26.47, a PEG ratio of 2.72 and a beta of 0.76.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Wednesday, January 28th. The company reported $0.96 EPS for the quarter, topping the consensus estimate of $0.65 by $0.31. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The business had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.36 billion. During the same quarter in the previous year, the firm posted $0.71 earnings per share. Teva Pharmaceutical Industries’s quarterly revenue was up 11.4% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. As a group, analysts forecast that Teva Pharmaceutical Industries will post 2.5 EPS for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.